BR3006

Boryung Pharmaceutical Co., Ltd · Phase 1 active Small molecule

BR3006 is a novel compound under development by Boryung Pharmaceutical Co., Ltd. Currently in Phase 1 trials, it is being evaluated for its pharmacokinetics and safety when co-administered with BR3006A, BR3006B, and BR3006C. The drug has no FDA label and is not yet approved for any indication.

At a glance

Generic name	BR3006
Sponsor	Boryung Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BR3006 CI brief — competitive landscape report
BR3006 updates RSS · CI watch RSS
Boryung Pharmaceutical Co., Ltd portfolio CI